Illumina (NASDAQ:ILMN) Issues Quarterly Earnings Results

Illumina (NASDAQ:ILMN) announced its quarterly earnings data on Thursday. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06), Zacks reports. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%.

Illumina Price Performance

Shares of ILMN stock traded down $1.88 during midday trading on Thursday, reaching $122.80. 2,145,761 shares of the company were exchanged, compared to its average volume of 1,834,142. Illumina has a 12 month low of $100.08 and a 12 month high of $156.66. The company has a market cap of $19.48 billion, a P/E ratio of -12.33 and a beta of 1.10. The company’s 50 day moving average price is $137.80 and its two-hundred day moving average price is $135.42. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Canaccord Genuity Group raised their price objective on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. Citigroup lowered shares of Illumina from a “buy” rating to a “neutral” rating and decreased their price target for the company from $190.00 to $165.00 in a report on Wednesday, December 11th. Morgan Stanley decreased their price target on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. TD Cowen lifted their price target on shares of Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, Stephens lifted their price target on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Eight analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $164.84.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.